Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Other hematologic neoplasm 1Breast 1

Conditions

Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × bemcentinib × Thoracic × Clear all
NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

BerGenBio ASA

Phase 2 Completed
99 enrolled 20 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡